Pinealon: Research & Studies

Research Overview#

The research literature on Pinealon spans hundreds of preclinical studies across multiple therapeutic areas. Below is a structured review of the key studies, systematic reviews, and identified research gaps.

Key Preclinical Studies#

Key studies and findings

• Khavinson et al., 2011, Rejuvenation Research. In vitro study across three preparations (rat cerebellar granule neurons, rat neutrophils, PC12 cells). Pinealon at 10–500 nM suppressed reactive oxygen species (ROS) in a dose-dependent fashion, reduced necrotic cell death under H2O2, delayed ERK1/2 activation in neurons exposed to homocysteine, and shifted PC12 cell-cycle distribution (fewer G1, more S/G2), suggesting antioxidant and genomic actions. Dosing included 100 nM fully preventing ouabain-induced ROS in neurons; 60-min preincubation used in PC12 H2O2 assays. Sample sizes for cell experiments were not explicitly stated in the retrieved excerpt. PubMed ID: not in retrieved context; DOI: 10.1089/rej.2011.1172.

• Kozina et al., 2008, Doklady Biological Sciences. In vivo rat hypobaric hypoxia model with intraperitoneal Pinealon 10 µg/kg/day for 5 days prior to hypoxia; n≈10 per group for acute hypoxia. Pinealon increased time to respiration arrest (72 s control vs 184±30 s, p<0.014), improved restitution metrics; in a prenatal hypoxia paradigm (five i.p. injections every other day, 10 µg/kg) Pinealon increased offspring per female (9±3 to 14±2, p<0.05) and reduced ex vivo cerebellar neuron vulnerability to oxidative insults (lower PI-positive cells; ROS responses modulated, with attenuation of NMDA excitotoxicity). PubMed ID: not in retrieved context; DOI: 10.1007/s10630-008-1003-x.

• Arutjunyan et al., 2012, International Journal of Clinical and Experimental Medicine. Prenatal hyperhomocysteinemia rat model induced by maternal methionine loading (1.0±0.01 g/kg/day). Pinealon 10 µg/kg i.p. daily for 5 days before methionine. Offspring cohorts for Morris water maze were ~23 pups per group; families per cohort n=6. Pinealon improved spatial orientation/learning, and reduced ROS accumulation and necrotic cerebellar neurons in offspring; offspring homocysteine remained elevated but cognitive performance was normalized relative to methionine-only. PubMed ID: not in retrieved context; DOI: not in retrieved context.

• Khavinson et al., 2017, Journal of Neurology and Neuroscience. Huntington’s disease model using mixed cortical–striatal cultures from YAC128 mice; mechanistic DNA-binding modeling. EDR restored medium spiny neuron spine morphology and was modeled to bind DNA at oligo(dCG) sites in the minor groove, supporting a direct nucleic-acid interaction hypothesis. Sample sizes and dosing not specified in retrieved text. PubMed ID: not in retrieved context; DOI: 10.21767/2171-6625.1000166.

• Khavinson et al., 2021, Pharmaceuticals. Alzheimer’s disease 5xFAD mouse model and in vitro amyloid synaptotoxicity. Daily i.p. KED 400 µg/kg from 2–4 months; EDR reported to prevent dendritic spine loss as well. Molecular docking predicted EDR binding motifs in promoters of AD-relevant genes (CASP3, NES, GAP43, APOE, SOD2, PPARA, PPARG), suggesting epigenetic regulation. Sample sizes and explicit EDR dosing were not in the retrieved excerpt. PubMed ID: not in retrieved context; DOI: 10.3390/ph14060515.

• Fedoreyeva et al., 2011, Biochemistry (Moscow). HeLa cell nuclear penetration and in vitro peptide–DNA binding assays with short peptides including Pinealon. Showed nuclear entry and sequence-specific binding to DNA/deoxyribooligonucleotides, consistent with direct genomic interactions proposed for Pinealon. PubMed ID: not in retrieved context; DOI: 10.1134/S0006297911110022.

• PubMed IDs for these items were not present in the retrieved context excerpts. We provide DOIs where available so that PubMed indexing can be cross-checked. If PubMed IDs are required, we recommend querying each DOI in PubMed.

Limitations

• Several reports originate from a limited investigator network and journals of variable rigor; human randomized trials with Pinealon were not identified in the retrieved context. Sample sizes for some cell and animal experiments were not fully specified in the excerpts. Results should be interpreted with these constraints in mind.

Vascular and Cardiovascular#

• Foundational PK/BBB studies: LC–MS/MS-based PK in rodents and non-human primates after oral and parenteral dosing, with plasma, CSF, and brain sampling; estimate bioavailability, half-life, and brain exposure; single and repeated dosing over 24–72 h and 2–4 weeks.
• GLP toxicology program: Two-species, single- and repeat-dose studies with maximum tolerated dose determination, safety pharmacology, genotoxicity, and immunogenicity; durations from acute to 90 days, per regulatory guidance.
• Rigorous preclinical efficacy: Randomized, blinded, dose–response studies in 5xFAD AD mice and hypoxia/ischemia models, including validated behavioral tests (e.g., Morris water maze), LTP, and dendritic spine analyses; pre-specified primary endpoints and powered sample sizes.
• Independent replication: Multicenter studies reproducing key efficacy and mechanistic results with harmonized protocols and transparent reporting, enabling meta-analysis.
• Mechanism-of-action validation: Biophysical binding assays (e.g., SPR) to histones/DNA, ChIP(-seq) to confirm promoter interactions, reporter assays for target genes, and CRISPR perturbation to test necessity/sufficiency; in vivo target engagement biomarkers aligned with PK/PD.
• Human trials: Phase 1 SAD/MAD, randomized, placebo-controlled PK/safety in healthy adults, followed by Phase 2 proof-of-concept RCT in MCI/early Alzheimer’s disease for 6–12 months with cognitive composites and fluid biomarkers; preregistered and CONSORT-compliant.

The Pinealon literature reports promising cellular and animal signals but is constrained by incomplete methods, missing PK/BBB and safety data, reliance on surrogate endpoints, and lack of preregistered human trials. A staged program—PK/BBB, GLP tox, rigorous randomized preclinical efficacy with replication, mechanism validation, and phased clinical trials—would most efficiently determine Pinealon’s therapeutic potential.

Neurological Research#

Synthesis of scope, methods, evidence, and conclusions.

• Khavinson 2020 (Molecules): Narrative review focused on EDR in Alzheimer’s disease mechanisms. Summarizes in vitro and animal neuroprotection (reduced ROS, modulation of MAPK/ERK, dendritic spine preservation) and cites small uncontrolled human observations (elderly memory, traumatic brain injury cohort). No formal search strategy or quantitative synthesis. Concludes EDR shows promising neuroprotective signals; safety described optimistically as lacking side effects, but systematic adverse event data are not presented.
• Khavinson 2021 (Molecules): Labeled as a systematic review of peptide regulation of gene expression across species. Provides mechanistic support that short peptides, including EDR, can interact with chromatin and DNA, but in the excerpt provides no Pinealon-specific clinical synthesis and lacks explicit search/inclusion details. Draws no firm clinical conclusions on Pinealon efficacy or safety.
• Ilina 2022 (Int J Mol Sci): Narrative review of ultrashort peptides in Alzheimer’s disease. Discusses EDR among others, focusing on epigenetic mechanisms and preclinical models. States peptides are promising “without reported side effects,” but provides no systematic human data or safety synthesis.
• Biology Bulletin Reviews 2016 (GDF11 article discussing Pinealon): Narrative overview referencing small human observations (post–head injury symptoms, cognitive testing; an athlete supplementation report) and animal/cell data (prenatal hyperhomocysteinemia model, reduced neuronal ROS). No systematic methods; no adverse event synthesis.

Overall conclusions on efficacy and safety.

• Efficacy: Reviews consistently describe preclinical neuroprotective effects of EDR/Pinealon (antioxidant actions, anti-apoptotic signaling, preservation of dendritic spines, behavioral improvements in animal models). Human evidence cited in reviews is limited to small, uncontrolled observations (e.g., elderly cognition, traumatic brain injury), insufficient to establish clinical efficacy. No randomized controlled trials or pooled estimates were identified.
• Safety: Reviews commonly claim an absence of reported side effects for ultrashort peptides, including EDR, but none present systematic adverse event collection or quantitative safety analyses. Therefore, safety in humans remains inadequately characterized beyond anecdotal or theoretical statements.

Critical appraisal. The available reviews are largely authored by overlapping groups, rely heavily on preclinical work, and lack rigorous, pre-registered systematic-review methodology in the examined excerpts. Potential biases include language bias toward Russian literature and publication bias. Consequently, certainty in conclusions about human efficacy and safety is low to very low.

Implication for practice. There are comprehensive narrative reviews and one broad, mechanistic “systematic review” mentioning EDR, but no Pinealon-specific meta-analyses or high-quality systematic reviews synthesizing clinical outcomes. Preclinical findings are encouraging, yet clinical efficacy and safety remain unproven and require well-designed randomized trials and systematic safety monitoring.

Systematic Reviews#

Objective. To determine whether systematic reviews, meta-analyses, or comprehensive reviews on Pinealon (EDR tripeptide) exist, and to summarize their conclusions on efficacy and safety.

Findings on existence and type of reviews. No Pinealon-specific meta-analyses were found. Several comprehensive narrative reviews discuss Pinealon/EDR, primarily mechanistic and preclinical, with limited human observational data. One broad “systematic review” on peptide regulation of gene expression includes EDR but is not Pinealon-specific and, in the excerpt examined, does not detail standard systematic-review methods or synthesize human efficacy/safety outcomes for Pinealon. Key sources are summarized in the embedded table.

Research Methodology#

We developed and executed a plan to identify methodological limitations and research gaps in the Pinealon (EDR; Glu–Asp–Arg) literature, then prioritized studies most needed to address them. Below we synthesize the findings and provide a concise, actionable research agenda.

Major methodological limitations

• Incomplete reporting and risk of bias: Many studies do not report doses, regimens, randomization, blinding, or sample-size/power calculations, and several are published in lower-quality venues. This limits reproducibility and inflates risk of bias.

• Sparse dosing and PK/BBB information: Aside from an intraperitoneal 10 µg/kg regimen in a rat hypoxia model, most reports omit dose, route, regimen, and provide no pharmacokinetics, bioavailability, or blood–brain barrier penetration data, leaving translational dosing uncertain.

• Limited controls and comparators: Many experiments use only vehicle controls or another short peptide (e.g., KED), with few dose–response studies or comparisons to standard-of-care agents, constraining interpretation of effect size and specificity.

• Randomization/blinding and power seldom documented: Preclinical studies often report small group sizes without justification and lack explicit randomization/blinding, increasing the likelihood of false positives.

• Heavy reliance on surrogate endpoints: Outcomes frequently emphasize cellular biomarkers (ROS, ERK activation, apoptosis markers), dendritic spine morphology, and in silico docking; validated behavioral/cognitive outcomes are sparse or show only trends.

• Reproducibility and independent replication: Findings are concentrated in few groups, with limited multicenter replication; mechanistic claims often depend on modeling rather than functional validation.

• Safety and toxicology data are minimal: Beyond general statements of tolerability, there is little systematic acute/chronic toxicology, safety pharmacology, genotoxicity, or immunogenicity data.

• Human evidence lacks rigor and preregistration: Reports of oral Pinealon added to standard therapy in small cohorts lack randomization, placebo control, detailed outcomes, and preregistration, providing insufficient evidence for efficacy or safety.

• Mechanism-of-action remains hypothetical: Proposed histone/DNA interactions and promoter binding are based on molecular modeling and associative changes without direct in-cell or in vivo target engagement evidence; BBB penetration is hypothesized, not measured.

• Pharmacokinetics, bioavailability, and BBB penetration across routes (oral, parenteral), including CSF/brain levels and half-life.

• GLP-compliant toxicology and safety pharmacology in two species, with immunogenicity and genotoxicity profiling.

• Rigorous, randomized, blinded preclinical efficacy with dose–response in disease-relevant models and validated behavioral endpoints, accompanied by electrophysiology and spine–behavior correlations.

• Independent multicenter replication of key findings and standardized reporting to enhance external validity.

• Mechanistic validation using direct assays of peptide–histone/DNA binding and target engagement in cells and in vivo; causal tests using genetic perturbations.

• Well-controlled, preregistered human trials, starting with PK/safety in healthy volunteers and progressing to proof-of-concept efficacy in target populations.

Highest-priority studies needed

Evidence Quality Assessment#

The evidence base for Pinealon currently consists primarily of preclinical studies. On the evidence hierarchy:

• Systematic reviews/meta-analyses: Limited availability
• Randomized controlled trials (human): Not completed
• Animal studies: Extensive body of research
• In vitro studies: Multiple cell culture experiments
• Case reports: Limited anecdotal evidence

Related Reading#

• Pinealon overview and research guide
• Pinealon dosing protocols
• Pinealon molecular structure